Cargando…

Functional Expression of Programmed Death-Ligand 1 (B7-H1) by Immune Cells and Tumor Cells

The programmed death-1 (PD-1) and its ligand PD-L1 (B7-H1) signaling pathway has been the focus of much enthusiasm in the fields of tumor immunology and oncology with recent FDA approval of the anti-PD-1 antibodies pembrolizumab and nivolumab and the anti-PD-L1 antibodies durvalumab, atezolimuab, an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gibbons Johnson, Rachel M., Dong, Haidong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2017
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5554355/ https://www.ncbi.nlm.nih.gov/pubmed/28848559 http://dx.doi.org/10.3389/fimmu.2017.00961

Ejemplares similares

Cbl-b Deficiency Mediates Resistance to Programmed Death-Ligand 1/Programmed Death-1 Regulation
por: Fujiwara, Mai, et al.
Publicado: (2017)

Variable Expression of Programmed Cell Death Protein 1-Ligand 1 in Kidneys Independent of Immune Checkpoint Inhibition
por: Hakroush, Samy, et al.
Publicado: (2021)

Safety and Efficacy of Programmed Cell Death 1 and Programmed Death Ligand-1 Inhibitors in the Treatment of Cancer: An Overview of Systematic Reviews
por: Ou, Shun-Long, et al.
Publicado: (2022)

Programmed Cell Death Tunes Tumor Immunity
por: Liu, Jing, et al.
Publicado: (2022)

Immune checkpoint molecules soluble program death ligand 1 and galectin‐9 are increased in pregnancy
por: Enninga, Elizabeth Ann L., et al.
Publicado: (2017)

Bioengineering and computational analysis of programmed cell death ligand-1 monoclonal antibody
por: Kalim, Muhammad, et al.
Publicado: (2022)

Programmed Cell Death-Ligand-1 expression in Bladder Schistosomal Squamous Cell Carcinoma – There’s room for Immune Checkpoint Blockage?
por: Madureira, Ana C.
Publicado: (2022)

Soluble monomeric human programmed cell death-ligand 1 inhibits the functions of activated T cells
por: Liang, Zhaoduan, et al.
Publicado: (2023)

Causal relationships between gut microbiota and programmed cell death protein 1/programmed cell death-ligand 1: A bidirectional Mendelian randomization study
por: Huang, Yu-Feng, et al.
Publicado: (2023)

Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1
por: Tai, Yu-Tzu, et al.
Publicado: (2018)

pH Low Insertion Peptide-Modified Programmed Cell Death-Ligand 1 Potently Suppresses T-Cell Activation Under Acidic Condition
por: Sun, Ying, et al.
Publicado: (2021)

Programmed Death-Ligand 1 Expression Potentiates the Immune Modulatory Function Of Myeloid-Derived Suppressor Cells in Systemic Lupus Erythematosus
por: Park, Min-Jung, et al.
Publicado: (2021)

Recent Findings in the Regulation of Programmed Death Ligand 1 Expression
por: Shen, Xiangfeng, et al.
Publicado: (2019)

B7-H1 Influences the Accumulation of Virus-Specific Tissue Resident Memory T Cells in the Central Nervous System
por: Pavelko, Kevin D., et al.
Publicado: (2017)

Interplay between programmed death-ligand 1 and non-coding RNAs
por: Ghafouri-Fard, Soudeh, et al.
Publicado: (2022)

IL-1β, But Not Programed Death-1 and Programed Death Ligand Pathway, Is Critical for the Human Th17 Response to Mycobacterium tuberculosis
por: Stephen-Victor, Emmanuel, et al.
Publicado: (2016)

Modulation of Gut Microbiota: A Novel Paradigm of Enhancing the Efficacy of Programmed Death-1 and Programmed Death Ligand-1 Blockade Therapy
por: Wang, Yiming, et al.
Publicado: (2018)

Emerging role of deubiquitination modifications of programmed death-ligand 1 in cancer immunotherapy
por: Jiang, Yao, et al.
Publicado: (2023)

Prognostic value of programmed cell death ligand 1 expression in patients with intrahepatic cholangiocarcinoma: a meta-analysis
por: Xian, Feng, et al.
Publicado: (2023)

The interaction between the soluble programmed death ligand-1 (sPD-L1) and PD-1(+) regulator B cells mediates immunosuppression in triple-negative breast cancer
por: Li, Xuejiao, et al.
Publicado: (2022)

Programmed Cell Death Ligand (PD-L)-1 Contributes to the Regulation of CD4(+) T Effector and Regulatory T Cells in Cutaneous Leishmaniasis
por: de Freitas e Silva, Rafael, et al.
Publicado: (2020)

The Change of Soluble Programmed Cell Death-Ligand 1 in Glioma Patients Receiving Radiotherapy and Its Impact on Clinical Outcomes
por: Ding, Xing-Chen, et al.
Publicado: (2020)

Comprehensive insights into the effects and regulatory mechanisms of immune cells expressing programmed death-1/programmed death ligand 1 in solid tumors
por: Liu, Min, et al.
Publicado: (2020)

Programmed Death-1/Programmed Death-Ligand 1-Axis Blockade in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Stratified by Human Papillomavirus Status: A Systematic Review and Meta-Analysis
por: Xu, Yimin, et al.
Publicado: (2021)

Anti-Tumor Potency of Short-Term Interleukin-15 Dendritic Cells Is Potentiated by In Situ Silencing of Programmed-Death Ligands
por: Versteven, Maarten, et al.
Publicado: (2022)

Clinicopathologic Significance and Prognostic Value of Programmed Cell Death Ligand 1 (PD-L1) in Patients With Hepatocellular Carcinoma: A Meta-Analysis
por: Li, Jing-Hua, et al.
Publicado: (2018)

Case Report: Complete Response of Primary Massive Hepatocellular Carcinoma to Anti-Programmed Death Ligand-1 Antibody Following Progression on Anti-Programmed Death-1 Antibody
por: Liu, Gang, et al.
Publicado: (2021)

Differential expression of programmed death 1 (PD-1) on various immune cells and its role in human leprosy
por: Tarique, Mohammad, et al.
Publicado: (2023)

Editorial: Progress of programmed cell death in antitumor immunity
por: Yan, Fangfang, et al.
Publicado: (2023)

Immunogenomic correlates of immune-related adverse events for anti–programmed cell death 1 therapy
por: Zhang, Lei, et al.
Publicado: (2022)

Interferon-γ/Interleukin-27 Axis Induces Programmed Death Ligand 1 Expression in Monocyte-Derived Dendritic Cells and Restores Immune Tolerance in Central Nervous System Autoimmunity
por: Casella, Giacomo, et al.
Publicado: (2020)

The role of the programmed cell death protein-1/programmed death-ligand 1 pathway, regulatory T cells and T helper 17 cells in tumor immunity: a narrative review
por: Zhang, Lanfang, et al.
Publicado: (2020)

Case report: Advanced primary squamous cell carcinoma in the periampullary area with upregulation of programmed cell death-ligand 1 expression and response to sintilimab immunotherapy
por: Wang, Baoshan, et al.
Publicado: (2023)

B7-H7 Is Inducible on T Cells to Regulate Their Immune Response and Serves as a Marker for Exhaustion
por: Luu, Khang, et al.
Publicado: (2021)

Decreased Expression of Programmed Death Ligand-L1 by Seven in Absentia Homolog 2 in Cholangiocarcinoma Enhances T-Cell–Mediated Antitumor Activity
por: Zheng, Hao, et al.
Publicado: (2022)

Soluble programmed cell death protein-1 and programmed cell death ligand-1 in sepsis
por: Banerjee, Debasree, et al.
Publicado: (2018)

Programmed cell death-1 and programmed cell death ligand-1 antibodies-induced dysthyroidism
por: Jaafar, Jaafar, et al.
Publicado: (2018)

Structure and Interactions of the Human Programmed Cell Death 1 Receptor
por: Cheng, Xiaoxiao, et al.
Publicado: (2013)

Inhibition of CCCTC Binding Factor-Programmed Cell Death Ligand 1 Axis Suppresses Emergence of Chemoresistance Induced by Gastric Cancer-Derived Mesenchymal Stem Cells
por: Wang, Qianqian, et al.
Publicado: (2022)

B7-H1 limits the entry of effector CD8(+) T cells to the memory pool by upregulating Bim
por: Gibbons, Rachel M., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_383hg2dh504qs9tup5jo0j6kde